title: Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study.
abstract: Fifty patients were scheduled to undergo removal of symmetrically positioned lower third molars in two separate appointments. Meloxicam 7.5 or 15 mg was once daily administered in a double-blind, randomized and crossover manner after the surgery for 4 days. Objective and subjective parameters were recorded for comparison of postoperative courses. Patients treated with 7.5mg meloxicam who underwent osteotomy reported higher pain scores at 1.5, 3, 4, 10, 12 and 16 h (P<0.05) and ingested a greater amount of rescue analgesic medication (P<0.05) than those who did not require osteotomy. A higher percentage of patients who underwent osteotomy medicated with 7.5mg meloxicam needed rescue medication as compared to those who did not require osteotomy (P<0.05). There was a similar mouth opening at suture removal compared with preoperative values for both doses (P>0.05). There were no significant differences concerning swelling observed on the 2nd or 7th postoperative days in comparison with baseline (P>0.05) between the two doses. Pain, trismus and swelling after lower third molar removal not requiring osteotomy can be successfully controlled by a dose regimen of 7.5mg meloxicam once daily. For more aggressive extractions 15 mg meloxicam is advisable.
authors.affiliation: Bauru School of Dentistry, University of São Paulo, Bauru/SP, Brazil.
authors.forename: A M
authors.initials: AM
authors.lastname: Calvo
authors.forename: V T
authors.initials: VT
authors.lastname: Sakai
authors.forename: F P M
authors.initials: FP
authors.lastname: Giglio
authors.forename: K C S
authors.initials: KC
authors.lastname: Modena
authors.forename: B L
authors.initials: BL
authors.lastname: Colombini
authors.forename: V
authors.initials: V
authors.lastname: Benetello
authors.forename: F C
authors.initials: FC
authors.lastname: Sakamoto
authors.forename: T M S
authors.initials: TM
authors.lastname: Freire
authors.forename: T J
authors.initials: TJ
authors.lastname: Dionísio
authors.forename: J R P
authors.initials: JR
authors.lastname: Lauris
authors.forename: A S
authors.initials: AS
authors.lastname: Trindade
authors.forename: F A C
authors.initials: FA
authors.lastname: Faria
authors.forename: C F
authors.initials: CF
authors.lastname: Santos
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004487:Edema / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D000077239:Meloxicam; D008964:Molar, Third / Q000601:surgery*; D010027:Osteotomy; D010149:Postoperative Pain / Q000517:prevention & control*; D016059:Range of Motion, Articular; D018709:Statistics, Nonparametric; D013843:Thiazines / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D014081:Tooth Extraction / Q000009:adverse effects; D014095:Tooth, Impacted / Q000601:surgery; D014313:Trismus / Q000517:prevention & control
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam